Methods. Z HER2:V2 was labelled with 188 Re using a gluconate-containing kit. Targeting of HER2-overexpressing SKOV-3 ovarian carcinoma xenografts in nude mice was studied for a dosimetry assessment.
INTRODUCTION
Overexpression of the human epidermal growth factor receptor type-2 (HER2) is associated with malignant transformation of cells and provides a growth advantage for tumors.
Treatment of HER2-expressing disseminated tumors with the anti-HER2 monoclonal antibody trastuzumab improves survival of patients with metastatic breast (1) and gastric cancer (2) . However, many tumors have a primary trastuzumab resistance or develop resistance during therapy despite preserved HER2 expression (2) . Conjugation of cytotoxic payloads (e.g. drugs or radionuclides) to tumor-targeting antibodies may enhance their antitumor effects and hence improve the response duration and overall response rate (3, 4) . Betaemitting radionuclides are considered as a promising form of cytotoxic payload, because of the cross-fire effect. The use of full-length antibodies for radionuclide therapy, however, is associated with a number of issues. The major obstacles are insufficient penetration in the tumor tissue, limiting the absorbed dose to tumors and slow clearance from the body causing second organ (mainly bone marrow) toxicity (5) . The use of smaller targeting agents, e.g. antibody fragments, would provide more efficient extravasation, better tumor penetration and more rapid clearance of an unbound tracer (6, 7) .
A promising approach for development of high affinity small-size tumor targeting agents is the use of engineered scaffold proteins (8) . Affibody molecules are the most studied class of scaffold proteins for in vivo radionuclide targeting. These high affinity ligands are based on a 58 amino acid (7 kDa) triple alpha-helical scaffold derived from domain B of staphylococcal protein A (9) . An affibody with picomolar affinity (22 pM) to the extracellular domain of HER2 has been selected earlier (10) . Affibody molecules labelled with different radionuclides have demonstrated efficient tumor targeting and high-contrast imaging of HER2-expressing tumors (11) . Two clinical studies have demonstrated that affibody molecules are non-toxic and non-immunogenic in humans (12, 13) . However, affibody molecules undergo renal excretion followed by efficient substantial renal re-absorption (14) . The use of residualizing labels has therefore resulted in a high retention of radionuclides in kidneys with a radioactivity concentration exceeding several fold the radioactivity concentration in tumors.
This would make the use of majority of radiometals (e.g. 177 Lu or 90 Y) unsuitable for radionuclide therapy (11) . An important feature of the HER2-targeting affibody molecules is their slow internalization by HER2-expressing cells (15) . This enables the use of nonresidualizing labels without appreciable reduction of tumor retention. On the contrary, rapid internalization of the affibody in proximal tubuli results in rapid clearance of nonresidualizing labels from kidneys (11, 16 Tc-and 188 Re-labelled peptides can be different (24, 25) .
Therefore, an evaluation of 188 Re-labelled Z HER2:V2 was necessary.
The goal of the current study was to evaluate the tumor-targeting properties and biokinetics of 188 Re-Z HER2:V2 in mice bearing HER2-expressing xenografts and based on dosimetry evaluation determine whether 188 Re-Z HER2:V2 might be a candidate for treatment of HER2-expressing tumors without severe second organ toxicity. Re generator (29.6 GBq) with 0.9% sodium chloride (Polatom). Affibody molecule Z HER2:V2 was produced and purified as described by (26) . All chemicals were purchased from Sigma-Aldrich. The HER2-expressing ovarian cancer cell line SKOV-3, 1.6x10 6 HER2 receptors per cell (ATCC), was used in cell studies. Cells were cultured in RPMI medium supplemented with 10% fetal calf serum, 2 mM L-glutamine and PEST (penicillin 100 IU/ml and 100 μg/ml streptomycin).
MATERIALS AND METHODS
Labelling and Stability Z HER2:V2 affibody molecules were site-specifically labelled with 188 Re using freeze-dried To evaluate serum stability, freshly labelled 188 Re-Z HER2:V2 (10 μL) was diluted in a serum sample (200 μL) to a concentration similar to the concentration in blood at the moment of injection, and incubated for 1h at 37 o C. The mixture was analyzed using radio SDS-PAGE. A sample of perrhenate was used as reference. The analysis was performed in duplicates.
In Vitro Evaluation
The specificity of binding and cellular processing of 188 Re-Z HER2:V2 by SKOV-3 cells were evaluated as described in (15 Table 1 ), GI tract and the remaining carcass were collected and weighed, and their radioactivity was measured in a NaI(Tl) well counter (PerkinElmer). Biodistribution data were corrected for decay and self-attenuation in samples, and organ uptake values were calculated as %IA/g except for the intestinal content, thyroid and the carcass, which was calculated as %IA per whole sample.
In vivo imaging was performed to obtain a visual confirmation of the biodistribution data. Human dosimetry. For dosimetry estimations in humans, uptake was extrapolated from animal data according to the percent kg/g method (29) .
Organ time-activity curves were calculated using organ weights of the 58 kg reference adult female (ICRP publication 23). Residence times were calculated as the area under the curve of bi-exponential fits to the animal organ time-activity curves. Remainder of the body residence time was based on radioactivity in carcass. Red marrow activity concentrations were conservatively assumed to be equal to whole blood concentrations. Absorbed doses were estimated using OLINDA/EXM 1.0. For calculation of absorbed dose to the intestines, either the ICRP 30 GI model was applied, using a fraction of 0.35% of the injected activity (the measured value at 1 h p.i.) entering the small intestine, or residence times calculated as above for small intestine and large intestine were used.
In tumor, SUV was assumed to be identical in humans as in rodents as well, and tumor absorbed doses were calculated assuming deposition of all beta energy within the tumor, neglecting any self-or cross-dose from gamma radiation. Dependence of absorbed dose on tumor volume was assessed using the Olinda/EXM 1.0 sphere model.
RESULTS

Labelling and Stability
The labelling method provided high yield (95.8±1%) with radiocolloid content below 1%.
Purification using disposable NAP-5 columns provided radiochemical purity over 99%. Upscaling experiments demonstrated that specific activity of 17.5 MBq/µg (116 GBq/µmol) can be obtained. 188 Re-Z HER2:V2 was stable in the formulation containing 6 mM ascorbic acid in PBS with 2% BSA (radiochemical purity of 99±1% during 4 h). In the absence of BSA, radiochemical purity was 94±2% after 4 h.
SDS-PAGE analysis was performed after incubation in murine blood plasma at 37 o C for 60 min. The main peak corresponded to the monomeric affibody molecule. No peaks indicating aggregation of affibody molecules or transchelation of the radionuclide to blood proteins were observed. The only other radioactivity peak had a path length equal to the path length of 188 Re-perrhenate. This peak contained less than 2% of the total activity at the end of the stability test (Supp . Fig 1) .
In Vitro Evaluation
In vitro specificity experiment showed that binding of 188 Fig 2) .
The cellular retention profile (Figure 1) showed a rapid drop of the activity during first hour followed by a slow decline with a biological half-life of 19.6 h. The total cellular retention of the radioactivity was 34.6±1.3% after 24 h of incubation at 37°C. The amount of internalized radioactivity of 188 Re-Z HER2:V2 was relatively low, less than 4% of total radioactivity after 24
h.
In Vivo Studies
The results of in vivo specificity test (Figure 2) showed that pre-saturation of HER2-receptors in xenografts with a parental Z HER2:342 decreased tumor uptake of 188 Re-Z HER2:V2 4.5-fold (p <0.005). This demonstrates a saturable character of the tumor accumulation and suggests its HER2-specificity. Small but statistically significant decrease of uptake in liver and increase in kidneys was also detected in this experiment.
Biodistribution of 188 Re-Z HER2:V2 in tumor bearing mice ( Re-Z HER2:V2 to re-oxidation in vivo. Kidneys demonstrated high initial uptake, which decreased rapidly. At 1 h p.i., the renal uptake was approximately equal to tumor uptake, and 4 h p.i., the tumor uptake was five-fold higher.
The tumor uptake was prominent as early as 20 minutes p.i. and was higher than the uptake in any normal organ except from kidneys. The tumor uptake had a maximum at 1 h p.i. (14±2 %IA/g) followed by decrease with a half-life of 15 h.
Scintillation-camera imaging, performed at 1 and 4 h after injection (Figure 3) , confirmed the results of the biodistribution experiments. The tumor xenografts were the only sites with prominent accumulation of radioactivity. Kidneys were visualized at 1 h after injection, but at 4 h p.i. only the HER2-expressing tumor xenografts were clearly visible.
Dosimetry
The evaluation of absorbed doses in mice for 188 Re-Z HER2:V2 is presented in Table 2 . The selfdoses to the majority of organs and tissues were much smaller than absorbed doses to tumors.
However, the size of a mouse body is comparable with the range of the beta-particles emitted by 188 Re (about 10 mm). For this reason, the total absorbed doses became much higher due to cross-irradiation. For example, the total absorbed dose to bone marrow was approximately 22% of the total absorbed tumor dose. This means that it was impossible to deliver a therapeutically meaningful absorbed dose to tumors (above 50 Gy) without lethal absorbed dose to the red marrow (around 8 Gy for mice). Performing therapy experiments with 188 Re-Z HER2:V2 therapy in mice was thus considered unethical under these circumstances and due to dimensional differences between mice and humans and range of beta particles, experiments in small animal murine models will generate irrelevant results.
The results of estimated absorbed dose calculations of 188 Re-Z HER2:V2 in humans using Olinda/EXM 1.0, are presented in Table 3 . In brief, tumor SUV was approximately constant after 1 h with a mean value of 3.3. Assuming local deposition of all beta energy, and no selfor cross-dose from gamma photons, this would result in an absorbed dose to tumor of 0.65 mGy/MBq. As shown in Figure 4 , absorbed doses to tumors with the weight of less than10 g would be slightly lower due to incomplete absorption of beta particles, whilst slightly higher absorbed doses are expected in larger tumors due to self-dose from gamma radiation.
Absorbed dose to tumor exceeded absorbed dose to kidney and bone marrow, 3.4-fold and 79-fold, respectively.
DISCUSSION
Radioimmunotherapy of radiosensitive hematological malignancies has proven to be successful, but treatment of more radioresistant solid tumors has so far been inefficient. The main reason is a failure to reach tumor absorbed doses above 50 Gy which are typically required to achieve response at external beam therapy (7).
Clinical experience with targeted radionuclide therapy using short peptides, particularly somatostatin analogues, demonstrated that the use of small targeting agents can solve problems of both poor tumor penetration and exposure of bone marrow (30) . Unfortunately, all small HER2-targeting radiolabelled agents, including antibody fragments, diabodies, DARPins and affibody molecules undergo considerable renal reabsorption (31) . In the case of residualizing radiometal labels, the renal uptake would be higher than tumour uptake for all these targeting proteins.
Our approach is based on the knowledge concerning cellular processing of affibody (Figure 1) showed low intracellular retention of radiocatabolites, the overall retention of radioactivity was reasonable with a biological half-life of 19.5 h. 188 Re-Z HER2:V2 has shown specific uptake in HER2-expressing xenografts in vivo (Figure 2) . The biodistribution study confirmed that unbound radioactivity was cleared very quickly from blood, and release of retained radioactivity from kidneys was much more rapid than from tumors ( Table 1) . Area under curve (AUC) for tumor exceeded AUC for blood 47-fold, bone 70-fold, and kidneys 2.8-fold. This suggested that the goal of delivering an efficient absorbed dose to tumors while sparing critical organs might be achievable.
We performed dosimetry calculations for 188 Re-Z HER2:V2 in mice using the anatomically realistic murine Moby phantom (27, 28) . The self-doses were in agreement with AUC data, however that total absorbed dose to bone marrow was much higher than the self-dose. It must be noted, that a high total absorbed dose to bone marrow is a phenomenon associated with the use of mice as an animal model. The maximum range of beta-particles from 188 Re is 10.4 mm (7), which is comparable with the dimensions of a mouse. For this reason, the cross-dose to bone marrow is much higher in mice than in humans. Delivery of therapeutically meaningful absorbed doses to tumors in mice would be associated with lethal absorbed doses to bone marrow.
Human dosimetry was much different due to the larger dimensions of the human body.
Upscaling of murine biodistribution data to human suggests that much lower absorbed doses will be delivered to radiosensitive organs in relation to tumor absorbed doses. A maximum absorbed dose of 2 Gy for bone marrow is generally accepted when planning radionuclide therapy; as such absorbed dose is associated with low risk of developing leukaemia (33) and low risk for acute bone marrow toxicity. An absorbed dose of 23 Gy is a commonly used absorbed dose limit for kidneys in peptide receptor radionuclide therapy (34) . In the case of absorbed dose of 130 Gy. This would permit delivering an absorbed dose well above 50 Gy without exceeding commonly accepted absorbed dose limits to critical organs. It has to be mentioned that upscaling from mice to humans is associated with apparent uncertainties, and a clinical imaging study would be required to obtain more reliable assessment of human dosimetry.
In addition to dosimetry estimations, there are other factors to consider when planning future therapy applications. 188 Re is produced via a generator in no-carrier-added form, which provides high specific activity. The short half-life of 188 Re-Z HER2:V2 , better retention of radioactivity in tumors than in kidneys. However, appreciable hepatobiliary excretion of 186 Re-maGSG-Z HER2:342 (20% of injected radioactivity was measured in the intestinal content at 4 h p.i.) caused a risk of high absorbed dose to intestines. Through re-engineering of affibody molecules by modifying of the chelator and its placement to Cterminus, as well as increasing hydrophilicity of N-terminus by amino acid substitution, we suppressed hepatobiliary excretion of 188 Re-Z HER2:V2 while keeping good tumor retention, low renal uptake and rapid clearance of unbound radioactivity. Thus optimal molecular design, including labelling strategy, may appreciably improve properties of scaffold-protein-based conjugates for radionuclide therapy.
Conclusion:
The affibody molecule, Z HER2:V2 can be labelled with 188 Re with a high yield with preserved picomolar affinity to HER2.
188
Re-Z HER2:V2 provides efficient targeting of HER2-expressing xenografts, rapid blood clearance and low uptake in kidneys and bones. Dosimetry calculations in man suggest that 188 Re-Z HER2:V2 may provide absorbed dose to tumors of more than 70 Gy while keeping absorbed dose to kidneys below 23 Gy and absorbed dose to bone marrow below 2 Gy. Thus, 188 Re-Z HER2:V2 is a promising targeting agent for radionuclide therapy against HER2-expressing tumors. 
SUPPLEMENTAL DATA
Labelling and stability 188 Re was obtained as perrhenate by elution of a 188 W/ 188 Re generator (29.6 GBq) with 0.9% sodium chloride (Polatom). Elution efficiency was 90%, when 4 ml of eluent was used.
For animal studies, the content of one freeze-dried kit was dissolved in100 μL 1.25 M sodium acetate, pH 4.2, and added to 100 μg of freeze-dried Z HER2:V2 . To the reaction mixture, 14-100 μL of 188 Re-containing generator eluate was added under argon gas. An equivalent of 220 μg ascorbic acid (2 mg/mL in 1.25 M sodium acetate buffer, pH 4.2) was added to the reaction vial. The mixture was incubated at 90°C for 60 min and then cooled at room temperature for 5 min. Thereafter, the total amount of ascorbic acid in the reaction vial is adjusted to 1 mg with a 5 mg/mL ascorbic acid solution in PBS (phosphate buffered saline) containing 2% BSA (bovine serum albumin). 188 Re-Z HER2:V2 was purified using disposable NAP-5 columns (GE Healthcare) pre-equilibrated and eluted with PBS containing 2% BSA. The final solution was diluted with an extra 100 μL PBS containing 2% BSA and 500 µg ascorbic acid to a final volume of 1 mL.
In up-scaling experiments, the content of a freeze-dried labelling kit vial (4 mg tin(II) chloride dihydrate, 400 µg disodium EDTA and 20 mg of sodium α-D-gluconate) was reconstituted in 400 µL 1.25 M sodium acetate, pH 4.2, containing 5mg/ml acid, and votrexed. The content of the vial was transferred to another vial containing 400 µg freeze-dried Z HER2:V2 and vortexed.
To this mixture, a 1mL (~7 GBq) of 188 Re-containing generator eluate was added, and the labeling mixture was votrexed carefully and incubated at 95 o C for 60 min. Further processing was performed as described above.
For measurement of the labelling yield and radiochemical purity, samples of 188 Re-Z HER2:V2
were analyzed using ITLC SG strips eluted with PBS. For measurement of reduced hydrolyzed rhenium colloid levels, a pyridine:acetic acid:water (5:3:1.5) mobile phase was used. The ITLC analysis was cross-calibrated by SDS-PAGE (Novex 4-12% Bis-Tris Gel, MES buffer, 200 V constant).
To estimate the shelf-life, the purity of 188 Re-Z HER2:V2 was measured at 1, 2 and 4h after purification using ITLC in duplicates.
In vitro evaluation
In vitro specificity test was performed using SKOV-3 cells. Briefly, a solution of 188 Re- 
